Fmr LLC Purchases 438,557 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

FMR LLC raised its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 15.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,309,175 shares of the biotechnology company's stock after purchasing an additional 438,557 shares during the quarter. FMR LLC owned approximately 10.87% of AnaptysBio worth $110,857,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Values First Advisors Inc. acquired a new position in AnaptysBio in the third quarter valued at approximately $49,000. nVerses Capital LLC grew its holdings in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Headlands Technologies LLC increased its position in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock worth $89,000 after acquiring an additional 2,900 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in AnaptysBio during the 3rd quarter valued at about $229,000.

AnaptysBio Trading Down 1.7 %

Shares of ANAB stock traded down $0.42 during trading on Thursday, reaching $23.66. 683,511 shares of the company's stock traded hands, compared to its average volume of 360,387. AnaptysBio, Inc. has a 1 year low of $15.78 and a 1 year high of $41.31. The firm's 50-day moving average is $27.31 and its 200 day moving average is $29.63. The company has a market capitalization of $719.97 million, a P/E ratio of -3.89 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Insider Activity

In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of the company's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now directly owns 7,020 shares in the company, valued at $279,536.40. This represents a 55.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ANAB has been the topic of several analyst reports. Wedbush reaffirmed an "outperform" rating and set a $42.00 target price on shares of AnaptysBio in a research report on Thursday, November 14th. BTIG Research lowered shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday. HC Wainwright cut their price target on shares of AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, August 15th. Finally, Guggenheim upped their target price on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $54.64.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.